Image Credit: Canva
When was the last time you measured your waistline? If you assume that BMI is the only number to focus on when it comes to your health, think twice. New research has revealed a shocking revelation—your waist circumference might be a far better predictor of men's cancer risk than BMI.
The study finds that for each 4-inch increase in waist size, a man's risk of cancer increases by a staggering 25%. Meanwhile, BMI, commonly regarded as the gold standard for assessing obesity, raises cancer risk by only 19% for the same weight gain. So, if you've been dismissing that pesky belly fat, it's time to take notice.
But why is your waistline so important? The reason is visceral fat—the hidden, deep fat that accumulates around your organs. Unlike other body fat, visceral fat is a stealthy troublemaker, causing inflammation, insulin resistance, and abnormal blood fat levels—all of which combine to create a cancer-perfect storm.
Obesity has been associated with an increased risk of numerous health conditions, including cancer, for decades. The research, though, indicates that a specific measure of the body—waist circumference—may be an even more reliable forecaster of cancer risk in men than the more frequently employed Body Mass Index (BMI). This finding emphasizes the need to pay particular attention to the distribution of fat and not merely to the weight of the body.
BMI has been the go-to measure for years for gauging health risks related to obesity. New research, though, that appears in The Journal of the National Cancer Institute indicates that waist measurement is a better predictor of cancer risk in men. According to the research, four more inches (10 cm) around the waist will add 25% to a man's cancer risk. Conversely, a 3.7 kg/m² rise in BMI (from a BMI of 24 to 27.7) increased cancer risk by only 19%.
Why is waist circumference a better predictor, then? Unlike BMI, which measures weight relative to height, waist circumference actually measures abdominal fat—specifically, visceral fat. This type of fat encircles internal organs and is also linked to higher levels of inflammation, insulin resistance, and abnormal blood lipids, all of which are factors in cancer growth. BMI, however, does not measure fat distribution, so two individuals with the same BMI can have very different levels of health risk depending on where fat is deposited on their bodies.
Interestingly, the research identified a significant difference between men and women when it came to waist circumference and cancer risk. Although waist circumference and BMI were linked with obesity-related cancers in women, the relationship was weaker than for men. An increase of 12 cm (4.7 inches) in waist size or a 4.3 rise in BMI (from 24 to 28.3) raised the cancer risk in women by just 13%—a much lower percentage than for men.
Experts credit this difference to the way that fat is stored in the body. Men are more likely to carry fat around the abdomen, especially as visceral fat, which is more metabolically active and associated with cancer-producing biological alterations. Women, by contrast, store fat in peripheral sites such as the hips and thighs, where it is less likely to drive systemic inflammation and metabolic disturbances.
A possible reason is that men tend to depot fat more in the visceral regions, whereas women tend to carry more subcutaneous and peripheral fat," wrote the researchers. "This may render waist circumference a more robust risk factor for cancer in men and account for why waist circumference provides additional risk information beyond BMI in men but not women."
The research used the International Agency for Research on Cancer (IARC) data to define obesity-related cancers. These cancers are esophageal (adenocarcinoma), gastric (cardia), colorectal, rectal, liver, gallbladder, pancreatic, renal, and thyroid cancers, and multiple myeloma and meningioma. In men, abdominal obesity is especially significant in raising the risk of these cancers through high levels of insulin and markers of inflammation.
For women, the research proposes that both waist circumference and hip circumference may give a more accurate estimate of visceral fat and cancer risk. "Adding hip circumference to risk models could strengthen the link between waist circumference and cancer, especially in women," researchers observed.
With these results, doctors advise men to be more mindful of their waistline than only their BMI. Waist size is an easy method to gauge health risk, and its maintenance through lifestyle changes might be the key to cancer prevention.
Track Your Waist Size: Regularly measure your waist circumference and try to keep it in a healthy range (below 40 inches for men, according to medical advice).
Eat a Balanced Diet: A diet containing high fiber, lean protein, and healthy fats can assist in limiting visceral fat gain.
Exercise Consistently: Regular exercise with a combination of aerobic and strength training will help maintain a healthy waistline.
Control Stress and Sleep: Persistent stress and inadequate sleep tend to cause weight gain, especially in the midsection of the body.
Regular Health Screenings: Early identification of cancer risk factors through regular screening can greatly enhance long-term health status.
Credit: iStock
It is a common belief that metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease (NAFLD)—is primarily associated with diet, sedentary lifestyles, and obesity. However, there are other factors as well that affect this aspect. Post-menopausal women experience a significantly higher incidence and faster progression of fatty liver disease, even when maintaining a stable body weight.
In Pre-menopausal women, estrogen plays a central role in metabolism by promoting healthy fat accumulation in subcutaneous tissue (below the skin) rather than around internal organs; it also increases insulin sensitivity and suppresses liver inflammation.
After menopause, when estrogen levels drop, this protective function is lost; there is redistribution of fat leading to more fat accumulation around internal organs, including the liver, thus leading to increased chances of NAFLD and also increasing insulin resistance. Needless to say, with age, our metabolic rate also goes down, which also plays a role in this.
The important part lies not only in understanding the above but in going further in early detection and prevention of menopause associated NAFLD. As we know, fatty liver is a silent disease and often does not cause any signs and symptoms till a very advanced stage.
First and foremost is to change lifestyle with advancing age, changing both the dietary habits and physical activity. Regular screening and monitoring are warranted with blood tests, routine metabolic panels, keeping a tab on weight, sugar, and cholesterol levels, and a basic ultrasound of the abdomen. For someone already diagnosed with second or third stage fatty liver, a simple non-invasive FibroScan can help monitor and assess the response to treatment.
Coming to the treatment part of NAFLD in post-menopausal women, being primarily a lifestyle disease, the core of management also lies in managing lifestyle. Medicines are available for treating and controlling NAFLD in conjunction with lifestyle management. Hormone replacement therapy (HRT), when initiated early in post-menopausal women for symptomatic relief, may offer secondary benefits by maintaining metabolic health. However, HRT should always be initiated after proper evaluation and expert guidance.
NAFLD is a silent epidemic and primarily a lifestyle disease; knowing about it and knowing the triggering and precipitating factors helps with understanding and prevention better. Menopause, being a natural biological phenomenon in every female’s life, makes it essential for us to know how it affects our liver health and overall health as well.
Credit: iStock
Being aware of personal and family cancer risk may be a critical component in women's knowledge and empowerment to make appropriate screening, prevention and treatment decisions.
Cancer treatment is fast evolving. Doctors are now focusing more on the person than the location or type of cancer and are considering the personal attributes of the patient and the disease. Genetic/genomic testing can complement this and can offer something more that could inform personalised cancer care.
Genetic testing screens for changes in the genes that could be passed down from parents. Some genetic mutations passed down from parents can make a woman more likely to get breast or ovarian cancer.
Having such a genetic change does not mean that a woman will develop cancer. This information will help her and her doctor discuss screening, monitoring and preventive action (if applicable) to reduce her risk.
This information may be useful for family members who could be at risk and should talk to their health care provider about their own risk.
There is a difference between genetic testing and genomic testing. Genetic testing is usually performed on blood or saliva to look for inherited changes or genetic predisposition. Genomic testing is usually performed on the tumour or blood to identify its molecular features to enable better understanding of its biology and biomarkers.
Cancer is not one disease and even two patients with the same type of cancer can have different biological characteristics, which can help doctors decide on the treatment and options that may be suitable for an individual patient.
Genomic testing could help to pinpoint features of a tumour that can be used to consider particular targeted treatments or other methods. But not all of them will be suitable or available to all patients based on the results of testing.
For women, knowing their family history and discussing any concerns with a doctor can be an important starting point. Genetic or genomic testing should not be done simply because it is available. A specialist may recommend testing based on factors such as family history, age at diagnosis and the type of cancer involved.
It is also important to understand test results correctly. Genetic counselling and discussions with an oncology specialist can help women understand what their results mean and what they do not mean.
Ultimately, genetic and genomic testing is not about predicting the future with certainty. It is about giving patients and doctors more information to make better-informed decisions.
As cancer care moves towards greater personalisation, the freedom to know your risk can become a powerful part of taking control of your health—helping women move from fear and uncertainty towards awareness, informed choices and personalised care.
(Dr. Jyoti Wadhwa, Principal Lead, Medical & Precision Oncology, Apollo Athenaa Women’s Cancer Center)
Credit: iStock
World Mosquito Day, observed on August 20, raises awareness about mosquito-borne diseases such as dengue, malaria, Zika, yellow fever, and chikungunya and the health risks they pose.
Among these diseases, dengue remains a major public health concern, affecting people across regions worldwide throughout the year.
Also read: India’s First Approved Dengue Vaccine: Takeda’s QDENGA Protects Against All Four Virus Serotypes
Dengue is typically associated with high fever, joint pain, and low platelet counts. However, severe dengue can affect the kidneys and lead to acute kidney injury (AKI).
Speaking to HealthandMe, nephrologists said kidney problems may not always cause symptoms early on, making monitoring particularly important in severe dengue.
Dr. Anupam Roy, Additional Director - Nephrology and Kidney Transplant, Aakash Healthcare Multi-Speciality Hospital, Dwarka, said that recovering from dengue requires careful fluid management, particularly in severe cases.
It is because the kidneys regulate fluids and electrolytes, and changes in circulation caused by dengue can temporarily disrupt their function.
Fever, vomiting, and poor fluid intake can cause dehydration, while severe dengue can cause plasma leakage. Both too little and too much fluid can create problems, making medical supervision important. In hospital, healthcare professionals monitor urine output and signs of dehydration, particularly in patients with complications or underlying health conditions.
After the acute phase, patients should gradually resume eating and drinking according to medical advice. Excessive fluid intake and self-medication should be avoided, particularly when medicines could place additional stress on the kidneys.
“So, it is the quantity issue that must be tackled,” Dr. Roy said.
According to Dr. Manoj Arora, Consultant Nephrologist, NephroPlus, a network of dialysis centers, warning signs include:
Some symptoms can overlap with severe dengue, including continuous vomiting, severe stomach pain, and bleeding.
Kidney injury is more likely in people with severe dengue or shock. Older people and those with diabetes, hypertension, obesity, or existing kidney problems may also face higher risk.
Seek medical attention for a drastic reduction in urine, new swelling, blood in the urine, worsening breathlessness, confusion, or continuous vomiting.
In hospitalized patients, monitoring is important when creatinine rises, electrolyte levels fluctuate — particularly potassium — or urine output continues to change.
Early recognition and appropriate management are key. Doctors may monitor:
Do not self-medicate or increase fluid intake without medical advice, particularly during severe dengue.
Reducing mosquito exposure and preventing mosquito breeding can help lower the risk of dengue.
© 2024 Bennett, Coleman & Company Limited